Ceriello, Antonio (7102926564)Antonio (7102926564)CerielloLalic, Nebjosa (13702597500)Nebjosa (13702597500)LalicMontanya, Eduard (6701745554)Eduard (6701745554)MontanyaValensi, Paul (7103187761)Paul (7103187761)ValensiKhunti, Kamlesh (7005202765)Kamlesh (7005202765)KhuntiHummel, Michael (58944460200)Michael (58944460200)HummelSchnell, Oliver (7006418720)Oliver (7006418720)Schnell2025-07-022025-07-022023https://doi.org/10.1016/j.jdiacomp.2023.108410https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148965767&doi=10.1016%2fj.jdiacomp.2023.108410&partnerID=40&md5=f8911bd1249d7eb3e1b967bcce17f261https://remedy.med.bg.ac.rs/handle/123456789/11884Aims: We used N-terminal pro-B-type natriuretic peptide (NT-proBNP) point-of-care testing (POCT) for heart failure risk stratification of individuals with type 2 diabetes for >10 years and hypertension. Methods: Overall 259 participants aged 50 years or older with type 2 diabetes (duration of >10 years), hypertension, and no overt cardiovascular disease (CVD) were recruited at two study centers. Patients' data were acquired and NT-proBNP levels were measured using the CARDIAC proBNP+ test (Roche) and the cobas h232 instrument (Roche). Participants were clustered into two groups according to their NT-proBNP concentration value: with NT-proBNP <125 pg/ml and with NT-proBNP ≥125 pg/ml. Results: Mean age of the participants was 66.1 ± 9.2 years, 55.2 % were female, 60.6 % (n = 157) had a NT-proBNP <125 pg/ml and 39.4 % (n = 102 ≥ 125 pg/ml). Differences were observed among those with low and high NT-proBNP in mean age (63.4 ± 8.8 years vs. 70.1 ± 8.2 years, p < 0.001), diabetes duration (15.4 ± 5.9 years vs. 17.9 ± 7.3 years, p = 0.003), and estimated glomerular filtration rate (eGFR) (86 ± 16 ml/min/1.73 m2 vs. 76 ± 20 ml/min/1.73 m2, p < 0.001). Conclusions: NT-proBNP POCT is practical and can be pragmatically targeted for screening people with type 2 diabetes and hypertension for heart failure risk stratification in routine clinical practice. © 2023Cardiovascular diseaseDiabetesHeart failureHypertensionNT-proBNPPoint-of-care testing